POOLED ANALYSIS OF OBJECTIVE COUGH FREQUENCY IN PARTICIPANTS WITH CHRONIC COUGH TREATED WITH GEFAPIXANT IN TWO PHASE 3 CLINICAL TRIALS (COUGH-1 AND COUGH-2)

被引：1
|
作者：
Smith, J. A. [1 ,2 ]
Morice, A. [3 ]
McGarvey, L. [4 ]
Pavord, I. [5 ]
Birring, S. S. [6 ]
Dicpinigaitis, P. [7 ,8 ]
Iskold, B. [9 ]
Li, Q. [9 ]
Tzontcheva, A. [9 ]
La Rosa, C. [9 ]
Muccino, D. [9 ]
机构：
[1] Univ Manchester, Div Infect, Immun & Resp Med, Manchester, Lancs, England
[2] Manchester Univ NHS Trust, Div Infect, Immun & Resp Med, Manchester, Lancs, England
[3] Hull York Med Sch, Cottingham, England
[4] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland
[5] Univ Oxford, Nuffield Dept Med, Oxford NIHR Resp BRC, Oxford, England
[6] Kings Coll London, Sch Basic & Med Biosci, Fac Life Sci & Med, Ctr Human & Appl Physiol Sci, London, England
[7] Albert Einstein Coll Med, Bronx, NY USA
[8] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[9] Merck & Co Inc, Kenilworth, NJ USA
来源：
THORAX | 2021年 / 76卷
关键词：
D O I：
10.1136/thorax-2021-BTSabstracts.171
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P61
引用
收藏
页码：A99 / A100
页数：2
相关论文
共 50 条
  • [31] Defining Minimal Clinically Important Differences (MCID) in Chronic Cough: Analyses of Objective Cough Counts from a Phase 2 Randomized Controlled Trial
    Nguyen, Allison M.
    Muccino, David
    Birring, Surinder
    Bacci, Elizabeth D.
    Vernon, Margaret K.
    Mines, Daniel
    Smith, Jaclyn A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB169 - AB169
  • [32] Responder Analyses for Patient-Reported Outcomes in a Pooled Analysis of Two Phase III Randomized Placebo Controlled Trials of Gefapixant, a P2X3 Receptor Antagonist for the Treatment of Chronic Cough
    Birring, S. S.
    Morice, A. H.
    Smith, J.
    McGarvey, L.
    Pavord, I. D.
    Nguyen, A. Martin
    Schelfhout, J.
    Dicpinigaitis, P.
    Iskold, B.
    Tzontcheva, A.
    Li, Q.
    Muccino, D.
    La Rosa, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [33] Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough
    Muccino, David
    Green, Stuart
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2019, 56 : 75 - 78
  • [34] DESIGN OF THE LANDMARK CALM-1 AND CALM-2 PHASE 3 CLINICAL TRIALS OF CAMLIPIXANT IN REFRACTORY CHRONIC COUGH
    Smith, Jacky
    Smith, Steven G.
    Iyer, Vivek
    Satia, Imran
    Chauret, Nathalie
    Harvey, Laurent
    Yang, Ronghua
    Garin, Margaret
    Bonuccelli, Catherine
    CHEST, 2024, 166 (04) : 97A - 99A
  • [35] The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough
    Lorcan McGarvey
    Mandel Sher
    Yury Grigorievich Shvarts
    Susan Lu
    Wen-Chi Wu
    Ping Xu
    Jonathan Schelfhout
    Carmen La Rosa
    Allison Martin Nguyen
    Paul A. Reyfman
    Amna Sadaf Afzal
    Lung, 2023, 201 : 111 - 118
  • [36] Burden of disease in a phase 3b trial of gefapixant in women with chronic cough and stress urinary incontinence
    Birring, Surinder S.
    Cardozo, Linda
    Dicpinigaitis, Peter
    Dmochowski, Roger
    Afzal, Amna S.
    Lu, Susan
    Nguyen, Allison Martin
    Yao, Ruji
    La Rosa, Carmen
    Reyfman, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [37] PATIENT-REPORTED IMPROVEMENTS WITH GEFAPIXANT, A P2X3-RECEPTOR ANTAGONIST, OVER 52 WEEKS IN TWO PHASE 3 CLINICAL TRIALS FOR REFRACTORY OR UNEXPLAINED CHRONIC COUGH
    Birring, S. S.
    Dicpinigaitis, P.
    Morice, A.
    Smith, J. A.
    McGarvey, L.
    Pavord, I.
    Nguyen, A. Martin
    Schelfhout, J.
    Tzontcheva, A.
    Li, Q.
    La Rosa, C.
    Muccino, D.
    THORAX, 2021, 76 : A99 - A99
  • [38] The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough
    McGarvey, Lorcan
    Sher, Mandel
    Shvarts, Yury Grigorievich
    Lu, Susan
    Wu, Wen-Chi
    Xu, Ping
    Schelfhout, Jonathan
    La Rosa, Carmen
    Nguyen, Allison Martin
    Reyfman, Paul A.
    Afzal, Amna Sadaf
    LUNG, 2023, 201 (02) : 111 - 118
  • [39] Improvements in cough severity and cough-related quality of life in a phase 2 trial (RELIEF) with the P2X3 antagonist BLU-5937 in refractory chronic cough (RCC)
    Birring, Surinder S.
    Smith, Jaclyn A.
    Morice, Alyn H.
    Sher, Mandel
    Hull, James H.
    Goldsobel, Alan B.
    Lanouette, Sylvain
    Li, Ella
    Harvey, Laurent
    Bonuccelli, Catherine M.
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [40] Early cough severity changes over the first 4 weeks of treatment with gefapixant in two phase 3 studies
    Birring, Surinder S.
    Dicpinigaitis, Peter
    Morice, Alyn
    Li, Qing
    Urdaneta, Eduardo
    Philip, George
    La Rosa, Carmen
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
12345